SEC Info - Biotelemetry, Inc. - ‘8-K’ for 2/26/20

i false i 0001574774 0001574774 2020-02-26 2020-02-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i February 26, 2020

i BioTelemetry, Inc.

(Exact name of registrant as specified in its charter)



i Delaware	i 000-55039	i 46-2568498
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)



i 1000 Cedar Hollow Road
i Malvern,	i Pennsylvania	i 19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: ( i 610) i 729-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $0.001 per share	i BEAT	i NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 26, 2020, BioTelemetry, Inc. issued a press release announcing its financial results for the fourth quarter ended December 31, 2019. Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. A copy of the press release is included herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit Number		Exhibit Title
99.1		Press release dated February 26, 2020
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	BioTelemetry, Inc.


Dated: February 26, 2020	By:	/s/ *Heather C. Getz*

		Name:	Heather C. Getz
		Title:	Executive Vice President and Chief Financial and Administrative Officer

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	2/26/20
	12/31/19	10-K, 4, 5, DEF 14A, SD
		List all Filings

Biotelemetry, Inc. – ‘8-K’ for 2/26/20

On: Wednesday, 2/26/20, at 4:14pm ET · For: 2/26/20 · Accession #: 1574774-20-29 · File #: 0-55039

Previous ‘8-K’: ‘8-K’ on 1/28/20 for 1/27/20 · Next: ‘8-K’ on / for 5/6/20 · Latest: ‘8-K’ on / for 2/9/21

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference